These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 2475715)
1. Cardiorenal effects of an orally active dopamine prodrug (TA-870) in patients with congestive heart failure. Kubota J; Kubo S; Nishimura H; Ueyama M; Kino M; Nakayama A; Hara M; Kawamura K J Cardiovasc Pharmacol; 1989 Jul; 14(1):53-7. PubMed ID: 2475715 [TBL] [Abstract][Full Text] [Related]
2. A novel orally active dopamine prodrug TA-870. I. Renal and cardiovascular effects and plasma levels of free dopamine in dogs and rats. Yamaguchi I; Nishiyama S; Akimoto Y; Yoshikawa M; Nakajima H J Cardiovasc Pharmacol; 1989 Jun; 13(6):879-86. PubMed ID: 2484082 [TBL] [Abstract][Full Text] [Related]
3. Central and renal hemodynamic effects of a new agonist at peripheral dopamine- and beta-2 adrenoreceptors (dopexamine) in patients with heart failure. Jamison M; Widerhorn J; Weber L; Campese V; Vasquez J; Hovanessian L; Rahimtoola SH; Elkayam U Am Heart J; 1989 Mar; 117(3):607-14. PubMed ID: 2537556 [TBL] [Abstract][Full Text] [Related]
4. Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure. Ungar A; Fumagalli S; Marini M; Di Serio C; Tarantini F; Boncinelli L; Baldereschi G; Valoti P; La Cava G; Olianti C; Masotti G; Marchionni N Crit Care Med; 2004 May; 32(5):1125-9. PubMed ID: 15190961 [TBL] [Abstract][Full Text] [Related]
5. A novel orally active dopamine prodrug TA-870. III. Positive inotropic effect and cardiorenal selectivity in anesthetized dogs. Nishiyama S; Yamaguchi I; Akimoto Y; Yoshikawa M; Nakajima H J Cardiovasc Pharmacol; 1990 Feb; 15(2):283-90. PubMed ID: 1689425 [TBL] [Abstract][Full Text] [Related]
6. A novel orally active dopamine (DA) prodrug TA-870. IV. Renal vasodilatory and negative chronotropic effects in anesthetized dogs: influence of DA1 and DA2 dopamine receptor selective antagonists. Nishiyama S; Yoshikawa M; Yamaguchi I J Cardiovasc Pharmacol; 1991 Apr; 17(4):560-7. PubMed ID: 1711621 [TBL] [Abstract][Full Text] [Related]
7. A novel orally active dopamine prodrug TA-870. II. Evidence that TA-870 is a dopamine prodrug. Nishiyama S; Yamaguchi I; Akimoto Y; Yoshikawa M; Nakajima H J Cardiovasc Pharmacol; 1989 Aug; 14(2):175-83. PubMed ID: 2476589 [TBL] [Abstract][Full Text] [Related]
8. Cardiorenal effects of atrial natriuretic factor administration in congestive heart failure: natriuresis and diuresis without hemodynamic alterations. Firth BG; Perna R; Bellomo JF; Toto RD Am J Med Sci; 1989 Apr; 297(4):203-8. PubMed ID: 2565086 [TBL] [Abstract][Full Text] [Related]
9. Beneficial acute effects of selective modulation of renal dopamine system by gamma-L-glutamyl-L-dopa in rabbits with congestive heart failure. Wang ZQ; Way D; Shimizu K; Fong F; Trigg L; McGrath BP J Cardiovasc Pharmacol; 1993 Jun; 21(6):1004-11. PubMed ID: 7687706 [TBL] [Abstract][Full Text] [Related]
10. A novel, orally active dopamine prodrug TA-870. V. Natriuretic and positive inotropic effects in rats: an assessment after chronic administration. Nishiyama S; Yamaguchi I J Cardiovasc Pharmacol; 1991 May; 17(5):768-77. PubMed ID: 1713992 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of ibopamine treatment in patients with advanced heart failure: purpose of a new therapeutic scheme with multiple daily administrations. Dei Cas L; Metra M; Nodari S; Visioli O J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S111-7. PubMed ID: 2483436 [TBL] [Abstract][Full Text] [Related]
12. Effects of converting-enzyme inhibition on cardiorenal hemodynamics in patients with chronic congestive heart failure. Kubo S; Nishioka A; Nishimura H; Kawamura K; Takatsu T J Cardiovasc Pharmacol; 1985; 7(4):753-9. PubMed ID: 2410718 [TBL] [Abstract][Full Text] [Related]
13. Dose-related hemodynamic and renal effects of dopamine in congestive heart failure. Beregovich J; Bianchi C; Rubler S; Lomnitz E; Cagin N; Levitt B Am Heart J; 1974 May; 87(5):550-7. PubMed ID: 4818699 [No Abstract] [Full Text] [Related]
14. Cardiovascular effects of a newly synthesized cardiotonic agent (TA-064) on normal and diseased hearts. Kino M; Hirota Y; Yamamoto S; Sawada K; Moriguchi M; Kotaka M; Kubo S; Kawamura K Am J Cardiol; 1983 Mar; 51(5):802-10. PubMed ID: 6829441 [TBL] [Abstract][Full Text] [Related]
15. Effects of prolonged infusion of human alpha calcitonin gene-related peptide on hemodynamics, renal blood flow and hormone levels in congestive heart failure. Shekhar YC; Anand IS; Sarma R; Ferrari R; Wahi PL; Poole-Wilson PA Am J Cardiol; 1991 Apr; 67(8):732-6. PubMed ID: 2006623 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of acute hemodynamic effects and pharmacokinetic behaviour of ibopamine in patients with severe heart failure. De Vita C; Triulzi E; Devizzi S; Colombo G; Palvarini M; Pocchiari F; Pataccini R Arzneimittelforschung; 1986 Feb; 36(2A):349-54. PubMed ID: 3707648 [TBL] [Abstract][Full Text] [Related]
17. Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. Yoshikawa M; Endo H; Komatsu K; Fujihara M; Takaiti O; Kagoshima T; Umehara M; Ishikawa H Drug Metab Dispos; 1990; 18(2):212-7. PubMed ID: 1971575 [TBL] [Abstract][Full Text] [Related]
18. Renal hemodynamic effects of vasodilation with nifedipine and hydralazine in patients with heart failure. Elkayam U; Weber L; Campese VM; Massry SG; Rahimtoola SH J Am Coll Cardiol; 1984 Dec; 4(6):1261-7. PubMed ID: 6501724 [TBL] [Abstract][Full Text] [Related]
19. Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study. Funasaki T; Tsutsumi M; Takase S; Tsuchishima M; Ueshima Y; Urashima S; Shimanaka K; Itoh T; Kawahara H Am J Gastroenterol; 1999 Sep; 94(9):2475-81. PubMed ID: 10484011 [TBL] [Abstract][Full Text] [Related]
20. Haemodynamic and renal effects of dopexamine after cardiac surgery in children. Habre W; Beghetti M; Roduit C; Girardin E; Vallotton M; Friedli B; Berner M Anaesth Intensive Care; 1996 Aug; 24(4):435-9. PubMed ID: 8862639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]